Highest-materiality recent filing
Recurring revenue rose 9% YoY to $12.6M (94% of total); total system sales fell to $836K from $2.6M.
LENSAR CFO Thomas R. Staab II to resign effective May 8, 2026
CFO Thomas R. Staab II notified company of resignation on April 10, 2026, effective May 8, 2026.
LENSAR Q4 revenue $16.0M (-4% YoY); recurring revenue up 17% to $12.7M
Net loss narrowed to $1.5M ($0.12/sh) from $18.7M loss a year ago, largely on warrant liability fair-value change.
LENSAR terminates merger with Alcon; retains $10M deposit; FTC intended to challenge deal
Merger agreement terminated effective March 16, 2026; FTC intended to seek injunction.
LENSAR secures $9.2M revolving credit facility from Wells Fargo secured by brokerage account
Revolving, non-purpose margin facility secured by a first-priority lien on a designated brokerage account at Wells Fargo.
LENSAR acquisition by Alcon faces FTC second request; closing expected H1 2026
LENSAR and Alcon continue cooperating with FTC on Second Request and review.
LENSAR Q3 revenue $14.3M, net loss $3.7M; ALLY installed base grows 77% YoY
Revenue $14.3M, +6% YoY; net loss $3.7M ($0.31/share) vs $1.5M loss in Q3 2024.
LENSAR Q2 revenue up 10% to $13.9M; ALLY placements surge; Alcon merger on track
Q2 2025 revenue $13.9M (+10% YoY); procedure volume up 23% to 52,100.
LENSAR stockholders approve merger with Alcon Research
15,983,846 votes for the merger, 26,033 against, 5,113 abstentions; 80.69% quorum.
FTC issues Second Request for LENSAR-Alcon merger, extending HSR waiting period
LENSAR and Alcon each received a Second Request from the FTC regarding the pending merger.
LENSAR Q1 revenue $14.2M (+34% YoY); net loss $27.3M on warrant liability
Total revenue $14.2M vs $10.6M in Q1 2024, driven by system sales and 33% procedure volume growth.
LENSAR Q1 revenue up 34% to $14.2M; net loss $27.3M on warrant liability adjustment
Total revenue $14.2M (+34% YoY); recurring revenue $11.5M (81% of total).
Alcon acquires LENSAR for $14.00/share cash plus CVR up to $2.75, total ~$430M
Per-share consideration: $14.00 cash plus contingent value right (CVR) of up to $2.75 if 614,000 cumulative procedures achieved by Dec 31, 2027.
LENSAR Q4 revenue $16.7M (+38% YoY); positive Adj. EBITDA; ALLY placements surge
Q4 revenue $16.7M, up 38% YoY; full-year revenue +27% YoY to ~$54M (implied).
LENSAR Q3 revenue $13.5M (+38% YoY); 24 ALLY placements; adj. EBITDA positive
Total revenue $13.5M, up 38% YoY; procedure volume +29% worldwide.
LENSAR Reports Q2 2024 Results with 17 ALLY Placements and Terminates Oertli Development Agreement
Q2 2024 revenue $12.6M, up 5% YoY; net loss $9.0M vs $8.8M loss in Q2 2023.
LENSAR Q1 revenue $10.6M (+28% YoY); net loss narrows to $2.2M
Total revenue $10.6M for Q1 2024, up 28% YoY; net loss $2.2M ($0.19 per share) vs $4.3M ($0.40) loss in Q1 2023.
LENSAR Q4 revenue up 18% to $12.1M; 44 ALLY systems placed in 2023, beating 30 target
Q4 2023 revenue $12.1M (+18% YoY); full-year revenue up 19% from 2022.
LENSAR Q3 revenue $9.8M (+26% YoY); net income $2.6M vs -$4.0M loss; ALLY installed base 39
Revenue $9.8M, +26% YoY ($7.7M); U.S. procedure volume +16% YoY.
LENSAR Q2 revenue up 49% YoY to $12M; ALLY installed base grows to 28 systems
Total revenue $12.0 million, +49% YoY; net loss $8.8M ($0.81/share) vs $6.8M loss prior year.
Gross proceeds of $20M from sale of 20,000 Series A Convertible Preferred Shares (stated value $1,000) and warrants to NR-GRI Partners, an affiliate of North Run Capital.
Revenue $8.3M, down 12% YoY; net loss $4.3M ($0.40/sh) vs $6.7M loss in Q1 2022.
LENSAR enters $20M securities purchase agreement with North Run Capital affiliate
Sold 20,000 Series A Convertible Preferred Shares at $1,000 stated value each for $20M gross proceeds.
LENSAR Q4 2022 revenue $10.2M (-9% YoY); net loss narrows to $2.5M from $3.9M
Q4 2022 total revenue $10.2M, down 9% from $11.2M in Q4 2021 due to lower South Korea procedure revenue.
LENSAR reports Q4 rev ~$10.2M (-9% YoY), FY rev ~$35.4M; ALLY System installations at 10
Q4 2022 revenue approximately $10.2M, down from $11.2M in Q4 2021; up 32% sequentially from Q3 2022.
LENSAR Q3 2022 revenue down 6% to $7.7M; net loss narrows to $4.0M; launches ALLY system
Revenue $7.7M, down 6% YoY; U.S. procedure volume up 9%, offset by South Korean reimbursement challenges.
LENSAR applies for CE Mark certification of ALLY System in European Union
Application for CE Mark certification of the ALLY Adaptive Cataract Treatment System submitted.
LENSAR announces first commercial ALLY System cases; Dr. Weinstock performs 15 surgeries
First commercial cases performed with ALLY System by Dr. Robert Weinstock at The Eye Institute of West Florida.
LENSAR Q2 revenue $8.0M (+1% YoY), net loss ($6.8M); FDA OK for ALLY system
Net loss of ($6.8M) or ($0.67)/share vs. ($4.4M) or ($0.47)/share in Q2 2021.
LENSAR holds commercial launch meeting for ALLY System after FDA clearance
LENSAR (LNSR) held commercial launch meeting week of June 27, 2022 for ALLY Adaptive Cataract Treatment System.
LENSAR receives FDA 510(k) clearance for ALLY Adaptive Cataract Treatment System
FDA 510(k) clearance received on June 9, 2022 for next-generation ALLY system.
LENSAR Q1 2022 revenue $9.3M (+33% YoY); net loss $6.7M; ALLY 510(k) under FDA review
Total revenue $9.3M, up 33% from $7.0M in Q1 2021; 89% from recurring sources.
LENSAR Q4 2021 revenue $11.2M (+35% YoY); full-year revenue up 31% to $34.2M; net loss narrows
Q4 revenue $11.2M vs $8.3M YoY; full-year revenue $34.2M (+31% vs 2020).
FDA accepts LENSAR's 510(k) for ALLY Adaptive Cataract Treatment System for substantive review
510(k) submission for next-gen ALLY system accepted for substantive review by FDA.
LENSAR Q3 2021 revenue $8.3M (+16% YoY), net loss widens to $6.2M
Revenue $8.3M, up 16% YoY; procedure volumes grew 23% over Q3 2020.
On May 25, 2026, the Board of Directors (the “Board”) of LENSAR, Inc. (the “Company”) appointed Michael A. Rossi to serve as the Company’s Interim Chief Financial Officer and principal financial officer, effective as of May 29, 2026.
On October 9, 2023, John P. McLaughlin notified the Board of Directors (the “Board”) of LENSAR, Inc. (the “Company”) of his intent to retire from the Board, effective October 31, 2023.
Also on May 12, 2023, in connection with the Offering and pursuant to the Purchase Agreement and subject to the closing of the Offering, the Board appointed each of Thomas B. Ellis and Todd B. Hammer to the Board effective immediately following the 2023 Annual Meeting of Stockholders.
Also on May 12, 2023, in connection with the Offering and pursuant to the Purchase Agreement and subject to the closing of the Offering, the Board appointed each of Thomas B. Ellis and Todd B. Hammer to the Board effective immediately following the 2023 Annual Meeting of Stockholders.
On January 11, 2022, the Board of Directors (the “Board”) of LENSAR, Inc. (the “Company”) appointed Kendra W. Wong, previously the Company’s Director of Financial Operations, to serve as the Company’s Principal Accounting Officer, effective immediately.
Max materiality 0.95 · Median 0.65 · Most common event earnings